$156,030.57 ownership Payment -- Roche/Genentech to Dr. Nicole Lopez

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Roche/Genentech made a $156.0K ownership payment to Nicole Lopez, a Oncology specialist in City, WA. This record details a significant ownership interest valued at over $156,000 held by Dr. Nicole Lopez in Roche/Genentech. The payment type is 'Ownership or Investment Interest', indicating a financial stake rather than a direct payment for services. This substantial financial relationship occurred in October 2025, as recorded in the CMS Open Payments database.

Patient Guidance: What This Payment Means for You

If you are a patient, understand that your doctor may have financial interests in pharmaceutical companies, which is publicly disclosed. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For an Oncology specialist, an ownership interest in a major pharmaceutical company like Roche/Genentech, valued at over $156,000, represents a significant financial relationship that warrants attention.

Regulatory Context: Sunshine Act Requirements

This disclosure falls under the Physician Payments Sunshine Act, requiring transparency in financial relationships between drug manufacturers and physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

• ownership-interest
• pharma-investment
• oncology
• cms-open-payments
• financial-relationship
• roche-genentech

Understanding ownership Payments

Ownership and investment interest payments represent dividends, returns, or other financial benefits from physician ownership stakes in pharmaceutical or medical device companies. These relationships represent the most direct form of financial interest and are subject to the strictest reporting requirements under the Sunshine Act.

Frequently Asked Questions About This Payment

What was this $156.0K payment for?

This was a ownership payment of $156.0K from Roche/Genentech to Nicole Lopez, categorized as "Ownership or Investment Interest". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Nicole Lopez accept pharmaceutical money?

Yes, Nicole Lopez received this $156.0K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Nicole Lopez's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this ownership payment?

A ownership payment of $156.0K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Oncology?

To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Nicole Lopez's relationship with Roche/Genentech?

The payment amount of $156,030.57 is a notable figure for an ownership interest. This $156.0K ownership payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Oncology?

The payment nature is specifically 'Ownership or Investment Interest', distinguishing it from other payment types.

What should patients do after learning about this payment?

If you are a patient, understand that your doctor may have financial interests in pharmaceutical companies, which is publicly disclosed.

What else should I know about this ownership payment?

Dr. Nicole Lopez, an Oncologist in WA, is the recipient of this ownership interest.

Related Reports

• View Dr. Nicole Lopez's full payment report
• Roche/Genentech full spending report
• Browse all Oncology payments
• Browse all payments in Washington
• Search for other payments